SCHEMBL3606461

SCHEMBL3606461

CCOC(=O)c1oc(-c2cccc(OC)c2)nc1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VDR P11473 9/20 0.59
PPARD Q03181 6/20 0.59
ESR1 P03372 2/20 0.59
THRA P10827 2/20 0.59
THRB P10828 2/20 0.59
RXRA P19793 2/20 0.59
PPARG P37231 2/20 0.59
PPARA Q07869 2/20 0.59
ESR2 Q92731 2/20 0.59
IKBKB O14920 1/20 0.55
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
TARBP2 Q15633 2/20 0.50
TSHR P16473 1/20 0.50
PDCD4 Q53EL6 1/20 0.50
MAPK1 P28482 1/20 0.50
TP53 P04637 2/20 0.48
HPGD P15428 2/20 0.48
HSD17B10 Q99714 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3621960 0.86 VDR (0.63) VDRPPARDESR1THRATHRB
SCHEMBL3536215 0.85 TARBP2 (0.68) IKBKBKDM4EALDH1A1SMN1; SMN2TARBP2
SCHEMBL25165083 0.83 IKBKB (0.72) VDRPPARDESR1THRATHRB
SCHEMBL11622665 0.83 TARBP2 (0.63) KDM4EALDH1A1SMN1; SMN2TARBP2TSHR
SCHEMBL28297240 0.83 TARBP2 (0.73) VDRPPARDESR1THRATHRB
SCHEMBL4884150 0.80 MMP2 (0.53) IKBKBKDM4EALDH1A1SMN1; SMN2TARBP2
SCHEMBL29158652 0.80 TARBP2 (0.57) VDRPPARDESR1THRATHRB
SCHEMBL25165105 0.78 IKBKB (0.57) VDRPPARDESR1THRATHRB
SCHEMBL22658100 0.77 ESR2 (0.58) ESR1ESR2KDM4EALDH1A1TARBP2
SCHEMBL22658069 0.76 TARBP2 (0.48) ESR1ESR2KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100022541-A1 Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors MUTABILIS SA (FR) 2010-01-28 US disclosed
EP-2104671-A2 SUBSTITUTED HETEROCYCLYLCARBONYLAMINO-ACETIC-ACID-DERIVATIVES AS INHIBITORS OF BACTERIAL HEPTOSE SYNTHESIS, METHODS FOR THEIR PREPARATION AND BIOLOGICAL APPLICATIONS OF SAID INHIBITORS Mutabilis SA (FR) 2009-09-30 EP disclosed
WO-2008038136-A2 SUBSTITUTED HETEROCYCLYLCARBONYLAMINO-ACETIC-ACID-DERIVATIVES AS INHIBITORS OF BACTERIAL HEPTOSE SYNTHESIS, METHODS FOR THEIR PREPARATION AND BIOLOGICAL APPLICATIONS OF SAID INHIBITORS MUTABILIS SA (FR) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022541-A1 Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors CBR1, OXER1, CBR3 VDR 625/4885PPARD 1791/4885ESR1 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.